Sunitinib malate
We are a manufacturer based in China. We specialize in providing high-quality Sunitinib malate for industrial clients across various sectors. Whether you need chemicals consultation or technical support, our team is here to help.
Category：Active Pharmaceutical Ingredients Own Brand：MT /MOQ:100KG /From China/ B2B only.
Introduction
Catalog ID80071763
CAS NO.341031-54-7
Purity 98%
MDL NumberMFCD08282795
Molecular FormulaC22H27FN4O2.C4H6O5
Molecular Weight532.566
Melting point: 197~199°C
| Item | Information |
|---|---|
| Mechanism of Action | Sunitinib malate is a multitargeted receptor tyrosine kinase inhibitor that blocks cellular signaling of several receptor tyrosine kinases, including platelet-derived growth factor receptors (PDGFR), vascular endothelial growth factor receptors (VEGFR), stem cell factor receptor c-KIT, FMS-like tyrosine kinase 3 (FLT3), and glial cell line-derived neurotrophic factor receptor (RET). These receptors play important roles in tumor angiogenesis and tumor cell proliferation. |
| Indications | – Treatment of advanced renal cell carcinoma (RCC).<br>- Treatment of gastrointestinal stromal tumor (GIST) in patients who are intolerant of or have developed resistance to imatinib.<br>- Treatment of pancreatic neuroendocrine tumors (pNET). |
| Storage Conditions | Sunitinib capsules should be stored at room temperature (20°C to 25°C; 68°F to 77°F), with excursions permitted between 15°C and 30°C (59°F and 86°F). |
| Special Precautions | – Thyroid Dysfunction: Monitor thyroid function during treatment, including hyperthyroidism, hypothyroidism, and thyroiditis.<br>- Hypoglycemia: Symptomatic hypoglycemia may occur; regular blood glucose monitoring is recommended.<br>- Osteonecrosis of the Jaw: Increased risk of osteonecrosis of the jaw when exposed concomitantly with bisphosphonates or dental disease/invasive dental procedures.<br>- Impaired Wound Healing: Discontinue sunitinib at least 3 weeks before planned surgery. |
| Embryo-Fetal Toxicity | Animal studies have shown that sunitinib can cause fetal harm. Pregnant women should be informed of the potential risks to the fetus and use effective contraception during treatment and for 4 weeks after discontinuation. |
Disclaimer: The above content is for reference and communication only among industry insiders, and does not guarantee its accuracy or completeness. According to relevant laws and regulations and the regulations of this website, units or individuals who purchase related items should obtain valid qualifications and qualification conditions.
If you're ready to take the next step, Leave your message below and we’ll reply soon. 20+ years of chemical manufacturing & export experience, a partner you can trust.
Inquiry
Factory & Shipment
